Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

PURPOSE: The Phase 3 ENDEAVOUR study evaluated revusiran, an investigational RNA interference therapeutic targeting hepatic transthyretin (TTR) production, for treating cardiomyopathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. METHODS: Patients with hATTR amyloidosis with cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Judge, Daniel P., Kristen, Arnt V., Grogan, Martha, Maurer, Mathew S., Falk, Rodney H., Hanna, Mazen, Gillmore, Julian, Garg, Pushkal, Vaishnaw, Akshay K., Harrop, Jamie, Powell, Christine, Karsten, Verena, Zhang, Xiaoping, Sweetser, Marianne T., Vest, John, Hawkins, Philip N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242280/
https://www.ncbi.nlm.nih.gov/pubmed/32062791
http://dx.doi.org/10.1007/s10557-019-06919-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242280/
https://www.ncbi.nlm.nih.gov/pubmed/32062791
http://dx.doi.org/10.1007/s10557-019-06919-4

Ejemplares similares